AstraZeneca Imfinzi, Imjudo combo gets approval in EU to treat liver, lung cancers
Roland Magnusson/iStock Editorial via Getty Images


The European Commission approved AstraZeneca's (NASDAQ:AZN) Imfinzi and Imjudo immunotherapy combinations to treat advanced liver and lung cancers.
Imjudo (tremelimumab) was approved in combination with Imfinzi (durvalumab) as a first line therapy for adults with advanced or unresectable hepatocellular carcinoma (HCC), a type of liver cancer.

In addition, Imfinzi in combination with Imjudo and platinum-based chemotherapy was approved to treat adult patients with metastatic (stage 4) non-small cell lung cancer (NSCLC).
The EC approval follows positive opinion from a panel of the European Medicines Agency (EMA) in December 2022.
The approvals were backed by data from phase 3 trials called HIMALAYA and POSEIDON.
"These approvals for Imfinzi and Imjudo bring critically needed, novel immunotherapy-based treatment regimens that will potentially deliver life-extending benefits for European patients with advanced liver and non-small cell lung cancers," said Dave Fredrickson, executive vice president, Oncology Business Unit, AstraZeneca,
The Imjudo and Imfinzi combo for lung cancer was approved in the U.S. in November 2022.